B Cell Lymphoma
From the Journals
Inhibitor may overcome ibrutinib resistance in MCL
The inhibitor, IACS-010759, decreased tumor growth and prolonged survival in mouse models of ibrutinib-resistant lymphoma.
From the Journals
Idelalisib shows long-term safety, efficacy for relapsed CLL
The long-term data confirm that the addition of idelalisib to rituximab significantly improves outcomes for patients with relapsed CLL. However,...
Opinion
Lessons from KEYNOTE-158 and the role of R-CHOP
Dr. Alan P. Lyss breaks down the clinical relevance of two recent studies in advanced cervical cancer and diffuse large B-cell lymphoma.
Conference Coverage
High-dose MTX-based chemo is well tolerated in older PCNSL patients
GLASGOW – A retrospective, real-world study suggests that older, fit patients can tolerate an intensive treatment regiment for primary central...
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
From the Journals
RIT consolidation may be an option for unfit MCL patients
Patients who could not undergo transplants had high rates of complete responses to radioimmunotherapy consolidation following induction...
From the Journals
Bendamustine/rituximab combo proves viable for comorbid CLL
Combination bendamustine and rituximab offers an effective treatment option for older, sicker patients with chronic lymphocytic leukemia.
From the Journals
In situ vaccination produced responses in indolent NHL
In situ vaccination induced regression of tumors that were directly targeted, as well as tumors that were not treated, in a small study of...
From the Journals
DA-EPOCH-R appears more toxic than standard R-CHOP in DLBCL
The National Clinical Trials Network is seeking to identify molecular subsets to see if specific chemotherapy platforms or targeted agents can...
Latest News
Polatuzumab outperforms pinatuzumab in non-Hodgkin lymphoma
Polatuzumab vedotin plus rituximab produced more durable responses than did pinatuzumab vedotin plus rituximab in patients with relapsed or...
Conference Coverage
Early data support R-BAC for post-BTKi mantle cell lymphoma
GLASGOW – The combination outperformed previously published data for other treatments in the relapsed/refractory setting.